Intranasal Pertussis Vaccine Candidate Shows Positive Pediatric Trial Results

ILiAD Biotechnologies' BPZE1 intranasal pertussis vaccine candidate demonstrated strong nasal and systemic immune responses with a favorable safety profile in children aged 6-17 during its Phase 2b SUPER clinical trial. Published in The Lancet Infectious Diseases, these findings build on prior adult studies and indicate no interference when co-administered with diphtheria and tetanus antigens, suggesting potential for broader public health application.